Dr. Myles Brown is Director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He obtained his B.S. in Biology from Yale and his M.D. from Johns Hopkins. Following training in Internal Medicine at the Brigham and Women’s Hospital, a Fellowship in Medical Oncology at the Dana-Farber and Postdoctoral Research at MIT, he joined the staff of the Dana-Farber and the faculty of Harvard Medical School. Brown’s research is focused on understanding the factors underlying the hormone dependence of breast and prostate cancers. He is recognized for three seminal discoveries including the role of p160 co-activators in steroid receptor action; the dynamic nature of co-regulator function; and the predominance of steroid receptors as enhancer-rather than promoter-binding factors.

Research Interests

The primarily focus of the work in my laboratory is the molecular understanding of the action of nuclear receptor transcription factors and their roles in prostate and breast cancers. My lab identified the p160 class of nuclear receptor interacting proteins and showed that these coregulators play an important role in the tissue and promoter selective action of steroid receptors and their ligands.

Membership Type


Election Year


Primary Section

Section 42: Medical Physiology and Metabolism

Secondary Section

Section 41: Medical Genetics, Hematology, and Oncology